Elena De Vita

List of Publications by Year in Descending Order

10 papers	95 citations	6 h-index	9 g-index
14 ext. papers	151 ext. citations	8.7 avg, IF	3.91 L-index

#	Paper	IF	Citations
10	Identification of the first structurally validated covalent ligands of the small GTPase RAB27A.. *RSC Medicinal Chemistry*, **2022**, 13, 150-155	3.5	0
9	A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. *Journal of the American Chemical Society*, **2021**, 143, 8911-8924	16.4	6
8	10 years into the resurgence of covalent drugs. *Future Medicinal Chemistry*, **2021**, 13, 193-210	4.1	23
7	Development of a fluorogenic ADAMTS-7 substrate. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2021**, 36, 2160-2169	5.6	0
6	Beyond targeted protein degradation: LD□ATTECs clear cellular lipid droplets. *Cell Research*, **2021**, 31, 945-946	24.7	2
5	Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6. *ChemMedChem*, **2020**, 15, 79-95	3.7	11
4	Design and Synthesis of Ionic Liquid-Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI-Coated Gold Nanoparticles. *ChemMedChem*, **2019**, 14, 686-698	3.7	1
3	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. *Acta Neuropathologica Communications*, **2018**, 6, 21	7.3	21
2	Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity. *Journal of Medicinal Chemistry*, **2018**, 61, 8859-8874	8.3	17
1	A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. *Journal of Biological Chemistry*, **2018**, 293, 12663-12680	5.4	11